Abcuro discloses Form D for equity offering worth up to $176.5 million
The Newton, Massachusetts biotechnology company reported $39.4 million sold as of a first sale date of August 7, 2026, with 23 investors participating.
Abcuro, Inc., a biotechnology company based in Newton, Massachusetts, filed a Form D notice with the Securities and Exchange Commission dated August 13, 2026, disclosing a new offering of equity securities. The total offering amount is listed as $176,522,953, with $39,383,108 already sold and $137,139,845 remaining to be sold.1
The filing lists the date of first sale as 2026-08-07.1 The company reported 23 investors who have already invested in the offering.1 Abcuro indicated it intends the offering to last more than one year.1
The offering is being made under the Rule 506(b) exemption.1 The company stated the offering is not being made in connection with a business combination transaction such as a merger or acquisition.1 The minimum investment accepted from any outside investor is listed as $0.1
The filing reports no sales commissions or finders' fees associated with the offering.1 Similarly, the amount of proceeds proposed for payments to executive officers, directors, or promoters is listed as $0.1
Related persons named in the filing include Chief Executive Officer John Alexander Martin, who signed the notice, along with directors Mark Pruzanski, Ron Hunt, Michael Dybbs, Ming Fang, and Sarah Boyce. The company's principal place of business is listed as 55 Chapel St Suite 200, Newton, Massachusetts.1 The filing does not specify how the proceeds from the offering will be used beyond the reporting categories required on the form.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.